Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aptose Bioscns (TSX: APS ) 0.9000 -0.0400 (-4.26%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 4,600 Open 0.9300 Bid (Size) 0.9000 (70) Ask (Size) 0.9800 (15) Prev. Close 0.9400 Today's Range 0.9000 - 0.9300 52wk Range 0.9000 - 6.900 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Aptose Announces Results from Annual and Special Meeting of Shareholders June 18, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress June 14, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Performance YTD -71.61% -71.61% 1 Month -25.62% -25.62% 3 Month -48.57% -48.57% 6 Month -69.80% -69.80% 1 Year -84.15% -84.15% More News Read More Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules June 03, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 31, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Reports Results for the First Quarter 2024 May 14, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 May 06, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Reports Results for the Fourth Quarter and Full Year 2023 March 26, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 March 18, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option January 31, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical January 26, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting December 09, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role November 30, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Reports Results for the Third Quarter 2023 November 09, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting November 02, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib October 30, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023 October 26, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th October 23, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference October 16, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Present at the Cantor Global Healthcare Conference September 18, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical September 06, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference August 24, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Reports Results for the Second Quarter 2023 August 10, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023 July 27, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance June 26, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Presents Highlights from Clinical Update June 10, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
